Abstract Introduction: Trophoblast cell surface antigen 2 (Trop-2), a transmembrane glycoprotein abundantly expressed in breast cancer tissues, has become a prominent target in precision cancer therapy, with Sacituzumab govitecan (SG) being the first antibody-drug conjugate (ADC) designed against it. Breast cancer, the most common malignancy in women, has a prognosis severely compromised by recurrence and metastasis.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Xiaohua
Contact Xiaohua, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack